Who is sponsoring NCT05015712?

NCT05015712 is sponsored by Han Yaling, MD.

What drugs are being tested in NCT05015712?

Interventions in NCT05015712: moderate intensity continuous training.

What condition does NCT05015712 study?

NCT05015712 studies Valve Disease, Aortic, Cardiac Rehabilitation.

Is NCT05015712 still recruiting?

NCT05015712 is currently status unknown. Last updated 14 July 2022.

Last reviewed 2022-07-14 · How we verify

NCT05015712

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of MICT on Cardiopulmonary Function in Patients After TAVI

Status unknown NA Last updated 14 July 2022

What this trial tests

NA trial testing moderate intensity continuous training in Valve Disease, Aortic in 66 participants. Status unknown.

Timeline

20 August 2021

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	Han Yaling, MD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	66
Start date	20 August 2021
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

moderate intensity continuous training

Conditions studied

Valve Disease, Aortic — all drugs for Valve Disease, Aortic →
Cardiac Rehabilitation — all drugs for Cardiac Rehabilitation →

Sponsor

Han Yaling, MD

Who can join

18 and older, any sex, with Valve Disease, Aortic or Cardiac Rehabilitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardiac rehabilitation (CR), particularly regular exercise, can improve the cardiopulmonary function, exercise capacity, and quality of life for patients undergoing transcatheter aortic valve implantation (TAVI). Consequently, the patients after TAVI will be enrolled in our randomized controlled trial to demonstrate if the moderate-intensity continuous training (MICT) can improve the cardiopulmonary function compared with the control group after receiving treatment for 12 weeks. Moreover, we will provide new insights regarding whether cardiac systolic function or cardiac diastolic function is mainly improved after regular exercise for TAVI patients. As a result, the principal hypothesis of our study is that MICT will improve the cardiopulmonary function and can extremely affect the cardiac diastolic function of patients with TAVI after the implementation of exercise for 12 weeks.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Long term efficacy and safety of MICT of cardiopulmonary function in patients after TAVR extended follow up of ENERGY study.
Li YS, Ren Q, Mu XB, Xu K, et al · · 2025 · cited 1× · PMID 40760006 · DOI 10.1038/s41598-025-13451-z
Immune checkpoint blockade in cancer: current insights and future horizons.
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, et al · · 2026 · PMID 41483376 · DOI 10.1007/s12672-025-04361-7

Verify or expand the search:

Other trials of moderate intensity continuous training

Trials testing the same drug.

NCT06408610 — Moderate Continuous Versus High Interval Intensity Training on Gut Dysbiosis and GLP1 Hormone in IBS · NA · completed
NCT06205563 — The Therapeutic Effect of Different Exercise Intensities on Weight Loss in Obese Children · NA · not yet recruiting
NCT03709095 — Sprint Interval Training During Rehabilitation After Spinal Cord Injury · NA · completed

Other recruiting trials for Valve Disease, Aortic

Currently open trials in the same condition.

NCT07197736 — DELINEATE-Prospective · recruiting
NCT06387446 — Allogeneic Valve Transplantation · NA · recruiting
NCT06449469 — The Nordic Aortic Valve Intervention Trial 4 (NOTION-4) · NA · active not recruiting

Other Han Yaling, MD trials

Trials by the same sponsor.

NCT06406218 — The Impact of Phase I Cardiac Rehabilitation on the Prognosis of AMI Patients After PCI · NA · recruiting
NCT03588611 — Reduce Bolus Injection of Bivalirudin · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05015712 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Han Yaling, MD
Last refreshed: 14 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05015712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing